CDC Warns of Hantavirus Outbreak Linked to Cruise Ship with Potential for International Spread

The Centers for Disease Control and Prevention (CDC) has issued a Health Advisory to alert healthcare providers and public health departments about a developing cluster of hantavirus cases, specifically linked to the Andes virus, originating from a multi-country cruise ship outbreak. While the risk of widespread transmission within the United States is considered very low, the CDC is taking precautionary measures to increase awareness and preparedness nationwide. The advisory provides guidance on identifying, testing, and handling potential cases, emphasizing the severe and potentially fatal nature of hantavirus pulmonary syndrome (HPS).

The situation came to light on May 2, 2026, when the World Health Organization (WHO) was informed of a cluster of severe acute respiratory illness on a cruise ship in the Atlantic Ocean, which resulted in two fatalities and one critically ill passenger. Subsequent laboratory tests confirmed the presence of hantavirus. By May 8, 2026, the WHO reported a total of eight cases, including six confirmed and two suspected, with three deaths attributed to the outbreak. The cruise ship, which departed from Ushuaia, Argentina, on April 1, 2026, visited remote locations including Antarctica, South Georgia Island, Tristan da Cunha, Saint Helena, and Ascension Island. The vessel carried 147 individuals from 23 different countries, and the extent of their contact with wildlife prior to or during the voyage remains unknown. Investigations are underway to assess potential exposure risks for American passengers who were on board or may have come into contact with infected individuals on aircraft.

In response to the outbreak, the CDC has dispatched a team to meet the cruise ship in the Canary Islands, Spain, following its journey from Cape Verde. This team is tasked with evaluating exposure risks among U.S. passengers and implementing appropriate monitoring protocols. The CDC is also collaborating with international partners to harmonize public health guidance and has already disseminated information to affected Americans through the State Department. Recognizing the potential for imported cases, the CDC is working to enhance awareness among travelers, public health agencies, laboratories, and healthcare professionals across the nation.

Hantaviruses are a group of viruses known to cause serious and potentially fatal illnesses. Transmission to humans typically occurs through contact with infected rodents, their excretions, or bodily fluids. In the Americas, hantaviruses can lead to hantavirus pulmonary syndrome (HPS), a severe lung infection with a significant mortality rate. The Andes virus, identified as the cause of this specific outbreak, is unique in that it has been documented to spread from person to person, although this is rare and usually requires close, prolonged contact with an infected individual, particularly in enclosed spaces, and exposure to their bodily fluids.

Symptoms of HPS typically manifest within 4 to 42 days after exposure. Early signs can be nonspecific, including fever, fatigue, and muscle aches, which can be easily mistaken for influenza or other common viral illnesses. Other early symptoms may include headaches, dizziness, chills, nausea, vomiting, diarrhea, and abdominal pain. The disease progresses to more severe respiratory symptoms such as coughing, shortness of breath, and chest tightness, usually appearing 4 to 10 days after the initial phase. Individuals are generally considered infectious only while symptomatic.

The early diagnosis of HPS can be challenging, as the virus may not be detectable in bodily fluids for the first 72 hours after symptom onset. Repeat testing is often necessary. Diagnostic tests for New World hantavirus antibodies are available at the CDC, some state public health laboratories, and commercial laboratories. Healthcare providers are advised to include HPS in their differential diagnoses for patients exhibiting compatible symptoms and with a history of potential exposure, such as close contact with a symptomatic individual or contaminated bodily fluids. Standard laboratory tests for common illnesses like COVID-19 and influenza should also be considered.

While there is no specific antiviral treatment for hantavirus infection, early supportive care is crucial for patient outcomes. Patients with suspected HPS can deteriorate rapidly, and prompt medical attention is vital. In severe cases, advanced medical interventions such as extracorporeal membrane oxygenation (ECMO) can significantly improve survival rates if initiated early. Survivors typically experience a relatively short critical phase and can recover quickly.

For healthcare providers, the CDC recommends implementing appropriate infection control measures for patients with suspected or confirmed Andes virus infection, including placement in an airborne infection isolation room and the use of personal protective equipment such as gowns, gloves, eye protection, and an N95 respirator. Clinicians should be vigilant for HPS in individuals presenting with symptoms and with relevant epidemiological risk factors within the 42 days preceding symptom onset.

Article by Mel Anara, based upon information from the Centers for Disease Control and Prevention (CDC)

Video Spotlight